Our Aspire deals have been pretty good compared what I'm used to seeing with early stage biotechs. In fact, one of my other biotechs recently did a financing where they sold shares and included warrants in the deal. Talk about dilution! I criticized that deal and used Leo and Aspire as an example of a much better way to acquire funding.

Quote:

---

ooops my bad.....I'm with you on P if it works in Phase2. OM trial has a ways to go...Looks like about 20 patients dosed as of Biotech conference....But who knows what's going on in Leo's mind. He sure does have a lot of choices to make a deal on....I just hope he doesn't choose Aspire. - takingabath

---